TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02457247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcichew D3
Description: Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcichew D3
Description: Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcichew D3
Description: Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcichew D3
Description: Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adcal-D3
Description: Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adcal-D3
Description: Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalcipos-D
Description: Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalcipos-D
Description: Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
Study: NCT03044275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed adhesive strip that in the future might be part of an ostomy device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
Study: NCT01989429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M518101
Description: 8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101
Description: 8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: M518101
Description: 8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
Study: NCT01492088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin IV infusion
Study: NCT02528396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro
Description: Injection at t0,or t+15 minutes or t-15minutes with test meal
Study: NCT02112305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic magnesium sulphate
Description: 2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50% magnesium sulphate
Description: magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
Study: NCT02184065

Intervention type: DRUG
Intervention: Meloxicam
Study: NCT02528396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Injection at t0,or t+15 minutes or t-15minutes with test meal
Study: NCT04153669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-NMES
Description: Exercise-NMES
Study: NCT05228405

Intervention type: OTHER
Intervention: All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
Description: All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
Study: NCT04464551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]D-0316 suspension
Description: Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
Study: NCT03694951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA behavioural counseling
Description: Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
Study: NCT03538093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Local Stabilization Exercise
Description: Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus a. activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase:4th-6th week: hot compress + electrotherapy IFT (fr: 4kHz, AMF 100Hz, modulation 20Hz, 20 mins), stabilizer training. Hamstring, quadriceps, gluteus maximus and psoas stretching, stationary bicycle without load. 7th-9th week: stabilizer training elevating a leg, stationary bicycle low load. 10th-12th week: 1kg to elevated leg on stabilizer training, stationary bicycle moderate load.
Study: NCT04153669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-No NMES
Description: Exercise-No NMES
Study: NCT02046161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopic examination in colon cleansing room
Description: All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
Study: NCT03538093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Global Stabilization Exercise
Description: Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: add obliques cross exercises in supine with contralateral leg, lumbopelvic bridge exercises, sitting on the edge of the bed. Day 3: add bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase: physiotherapy: 4th-6th week: hot compress + electrotherapy IFT, lumbopelvic bridge exercises, obliques cross exercises. Hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, stationary bicycle low load. 10th-12th week: physiotherapy, side plank, unilateral bridge, stationary bicycle moderate load.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Mixed Stabilization Exercise
Description: Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus abdominis activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~4th-6th week: hot compress + electrotherapy IFT, stabilizer training, hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, change stationary bicycle load to low load. 10th-12th week: physiotherapy, advanced global exercise (side plank), unilateral bridge,stationary bicycle moderate load.
Study: NCT04240431

Intervention type: DIAGNOSTIC_TEST
Intervention: Probing /irrigation of lacrimal passages
Description: Probing of the lacrimal passage was done using #00 Bowman's lacrimal probe which can reveal any narrowing (resistance) or obstruction (soft stop) of the canaliculi during its advancement from punctum towards the lacrimal sac.
Study: NCT03533088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospitalized rehabilitation
Description: Patients will recive a rehabilitation prgram at the clinic twice in a week until the post-operative 12. weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Description: Patients will recive a home program once in a two weeks until the 6. weeks of post-operative period. Then will start to recieve a rehabilitation program ar the clinic once in a week auntil the 12. week of the post-operative period.
Study: NCT03506620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: 20 cc of saline will be injected in the form of a QL block as a placebo.
Study: NCT01979679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone 80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone 160 mg
Study: NCT04198883

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Protheracytes
Description: Intramyocardiac (LV) injection of stem cells with a dedicated catheter
Study: NCT00509327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisacodyl
Description: 10mg capsule twice daily from one day preoperatively to day three postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glucosemonohydricum
Description: 10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
Study: NCT04245709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Description: The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
Study: NCT02984670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist.
Description: The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
Study: NCT00185302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
Description: MS-275, 3 mg on Days 1 and 15 of a 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
Description: MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
Study: NCT00127881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-CD4 (zanolimumab)
Description: Monoclonal Antibody, 12 weekly infusions.
Study: NCT00853892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled-Release Oxycodone Hydrochloride 40 mg tablet
Description: Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyContin® 40 mg tablet
Description: OxyContin® 40 mg tablet, single dose fasting
Study: NCT03335202

Intervention type: DIAGNOSTIC_TEST
Intervention: analysis of microbiome
Description: microbial profiling by next generation sequencing
Study: NCT01355614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576

Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Study: NCT02516501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MyAmino
Description: MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
Study: NCT01822171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge medication counseling from a pharmacist
Description: Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
Study: NCT02516501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MyAmino
Description: MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: betaquik
Description: betaquik is a medium chain triglyceride (MCT) emulsion. One bottle is 225ml corresponding to 45g MCT fats.
Study: NCT01822171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home medication if needed
Description: Patient will be provided with medication to take home, when needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up visit at Medication Therapy Management clinic
Description: This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
Study: NCT02516501

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radio(chemo)therapy
Description: Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radio(chemo)therapy
Description: Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
Study: NCT04259567

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytokine absorption
Description: Use of CytoSorb absorber
Study: NCT01204437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin, Cyclophosphamide
Description: 4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide, Methotrexate, 5 FU
Description: 6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
Study: NCT02516501

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radio(chemo)therapy
Description: Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
Study: NCT01204437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Nab-Paclitaxel
Description: 6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
Study: NCT01978509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High volume prep (Golytely)
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
Study: NCT01692912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Care
Description: Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6
Study: NCT01746940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine HCl 4% Topical Solution
Description: Cocaine HCl 4% Topical Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine HCl 10% Topical Solution
Description: Cocaine HCl 10% Topical Solution
Study: NCT01339936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose sodium, glycerin and polysorbate 80
Description: 1 drop in each eye three times a day for a period of 30 (± 4) days
Study: NCT02901600

Intervention type: OTHER
Intervention: Detection of the expression of DMTB1 by immunohistochemistry

Intervention type: OTHER
Intervention: Detection of the expression of DMTB1 by immunohistochemistry

Intervention type: OTHER
Intervention: Detection of the expression of DMTB1 by immunohistochemistry
Study: NCT01122979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin (insulin isophane)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
Study: NCT01746940

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Solution
Description: Placebo Topical Solution
Study: NCT01122979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
Study: NCT02784392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Comparator
Study: NCT03358602

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective neck dissection
Description: Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
Study: NCT02273102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: 45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: 45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: 45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
Study: NCT00817934

Intervention type: DRUG
Intervention: AB PREP
Description: Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
Study: NCT02694601

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: 4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine low dose
Description: 4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine high dose
Description: 4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
Study: NCT04249401

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto)
Description: NOAC, reduced dose

Intervention type: DRUG
Intervention: Apixaban
Description: NOAC, reduced dose

Intervention type: DRUG
Intervention: Dabigatran
Description: NOAC, reduced dose

Intervention type: DRUG
Intervention: Warfarin
Description: VKA
Study: NCT03457714

Intervention type: BEHAVIORAL
Intervention: Guided ICBT for persons with Spinal Cord Injury
Description: An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.

Intervention type: OTHER
Intervention: Survey
Description: Caregiver burden and mental health will be assessed through online questionnaires.
Study: NCT04096586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red juice
Description: To determine the effects of red juice on satiety and gut health

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon juice
Description: To determine the effects of watermelon juice on satiety and gut health
Study: NCT03542019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prosthesis
Description: Replacement of missing tooth structure using Lithium disilicate porcelain
Study: NCT02043184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) Reminders
Description: Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) Reminders
Description: Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.